Over the past year, many prominent psychiatrists have been exposed by the Wall Street Journal for having unscrupulous dealings with the pharmaceutical industry. The following articles are in relation to Paxil-Seroxat and how this dangerous , harmful and defective medication was promoted by the top brass of Psychiatry. The words “bias” , “conflict of interest” and “corruption” don’t even come close to describing the magnitude of the crime against humanity involved here. Check out some of these articles from the Wall Street Journal for more on this :
Another Emory Psychiatrist Draws Fire for Payments From Glaxo
By David Armstrong
More details are coming out about the relationship between Emory University psychiatrist Zachary Stowe and GlaxoSmithKline, which made payments to Stowe at the same time he was conducting federal research about the use of antipressants, such as Glaxo’s Paxil, in pregnant women.
Emory has reprimanded Stowe, who was instructed to immediately eliminate conflicts related to current federal grants. In a statement, the school said Stowe had informed it of “previously unreported activities and has disclosed his failure to abide by Emory policies.” Stowe, through the university, declined an interview request. Here’s more on the story.
In a letter this month to Emory, Sen. Charles Grassley said records he obtained from Glaxo indicated Stowe was paid $154,400 by the drug company in 2007 and $99,300 during the first 10 months of 2008. Stowe is listed as the primary investigator on at least three National Institutes of Health grants, beginning in 2003 and continuing through last year, that involve antidepressant use in pregnant women and the effects on children delivered by those women.
Meanwhile, Stowe outlined some dealings with Glaxo in a deposition last year taken as part of a lawsuit claiming that Paxil isn’t safe for pregnant women. Stowe was questioned in detail about a 2000 email from an outside public-relations firm to a marketing executive at Glaxo about a planned press release for a new study. The study, conducted by Stowe, found Paxil is safe for breast-feeding mothers. The PR firm’s email to Glaxo reads:
Please review the attached press release and forward me any comments/edits. As you may know, Dr. Stowe is on board for publicity efforts and Sherri and I are coordinating time to meet with him next week to arm him with key messages for this announcement, which is slated for early February. We are sending the release for his review at the same time in efforts to secure distribution on Emory letterhead (as you know, would provide further credibility to data for the media).
In the deposition, Stowe said the quotes in the press release were his own. “They wrote it, we said it,” Stowe said of the involvement of the public-relations agency. As for the assertion by the PR official that Stowe was being provided with “key messages,” the psychiatrist called that “just typical public relations crap” and he said in the deposition he never received help from the PR officials.
Stowe is the second Emory psychiatrist to run into problems related to his work with the drug industry. Charles Nemeroff stepped down as chairman of the psychiatry department last year after an Emory investigation concluded that he failed to report more than $800,000 he received from Glaxo from 2000 to 2006. In December, he said in a statement that he acted “in good faith to comply with the rules as I understood them to be in effect at the time.”
Doctor Didn’t Disclose Glaxo Payments, Senator Says
The senator alleges Dr. Nemeroff did not report that he was giving promotional talks for Glaxo on the anti-depressant Paxil.
By Sarah Rubenstein
Emory University continues to feel the heat over Sen. Charles Grassley’s investigation into conflicts of interest among doctors: The federal government is investigating whether Emory misled the National Institutes of Health over payments that prominent psychiatrist Charles Nemeroff received from GlaxoSmithKline, the WSJ reports.
Nemeroff stepped down from the chairmanship of Emory’s psychiatry department, but remains a professor there, amid allegations that he failed to disclose hundreds of thousands of dollars in payments from Glaxo, maker of antidepressant Paxil.
A probe by the inspector general for the Department of Health and Human Services is looking into whether Emory failed to tell the NIH about Nemeroff’s potential conflicts, or misrepresented the kind of work he did for Glaxo, as he served as lead investigator on NIH-funded research on five Glaxo drugs for use as antidepressants, WSJ says. The NIH last year suspended a $9.3 million grant to Emory amid Grassley’s probe.
Grassley has been encouraging the HHS inspector general to look into the matter to make sure “Emory did not, either directly or indirectly, mislead the NIH about the nature of Dr. Nemeroff’s promotional talks for GSK and advocacy on behalf of Paxil,” as he wrote (click the letter at right).
A spokeswoman for the inspector general wouldn’t comment on whether the office was investigating. Emory said it will continue to cooperate with NIH; NIH declined to comment. Nemeroff didn’t return the WSJ’s call but has said before he believes he complied with relevant disclosure requirements.